Vir Biotechnology: Strong Balance Sheet But Commercial Prospects Await More Clarity

Red arrow


In late December, I recommended Vir Biotechnology, Inc. (NASDAQ:VIR) as a speculative Buy due to its long-term cash availability, experienced management team, collaborations with significantly large commercial companies such as GSK and progressing pipeline. The company has recently released its

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *